Abstract:Adaptive immune response modulation has taken a central position in cancer therapy in recent decades. Treatment with immune checkpoint inhibitors (ICIs) is now indicated in many cancer types with exceptional results. The two major inhibitory pathways involved are cytotoxic T-lymphocyte-associated protein 4 (CTLA4) and programmed cell death protein 1 (PD-1). Unfortunately, immune activation is not tumor-specific, and as a result, most patients will experience some form of adverse reaction. Most immune-related adverse events (IRAEs) involve the skin and gastrointestinal (GI) tract; however, any organ can be involved. Cardiotoxicity ranges from arrhythmias to life-threatening myocarditis with very high mortality rates. To date, most treatments of ICI cardiotoxicity include immune suppression, which is also not cardiac-specific and may result in hampering of tumor clearance. Understanding the mechanisms behind immune activation in the heart is crucial for the development of specific treatments. Histological data and other models have shown mainly CD4 and CD8 infiltration during ICI-induced cardiotoxicity. Inhibition of CTLA4 seems to result in the proliferation of more diverse T0cell populations, some of which with autoantigen recognition. Inhibition of PD-1 interaction with PD ligand 1/2 (PD-L1/PD-L2) results in release from inhibition of exhausted self-recognizing T cells. However, CTLA4, PD-1, and their ligands are expressed on a wide range of cells, indicating a much more intricate mechanism. This is further complicated by the identification of multiple co-stimulatory and co-inhibitory signals, as well as the association of myocarditis with antibody-driven myasthenia gravis and myositis IRAEs. In this review, we focus on the recent advances in unraveling the complexity of the mechanisms driving ICI cardiotoxicity and discuss novel therapeutic strategies for directly targeting specific underlying mechanisms to reduce IRAEs and improve outcomes.

Changes in tumor and cardiac metabolism upon immune checkpoint

Metabolic Implications of Immune Checkpoint Proteins in Cancer

Cell Intrinsic and Systemic Metabolism in Tumor Immunity and Immunotherapy

Targeting T-cell metabolism to boost immune checkpoint inhibitor therapy

Metabolic modulation of immune checkpoints and novel therapeutic strategies in cancer

Immuno-Metabolism: The Role of Cancer Niche in Immune Checkpoint Inhibitor Resistance

The interplay between metabolic adaptations and diet in cancer immunotherapy

Targeting Metabolism to Improve the Tumor Microenvironment for Cancer Immunotherapy

Immune Checkpoint Inhibitors and Cardiac Toxicity: An Emerging Issue

Molecular fingerprints of cardiovascular toxicities of immune checkpoint inhibitors

Exploring the Mechanisms Underlying the Cardiotoxic Effects of Immune Checkpoint Inhibitor Therapies

Altered cancer metabolism in mechanisms of immunotherapy resistance

Immune Checkpoint Inhibitor Associated Myocarditis and Cardiomyopathy: A Translational Review

Metabolic basis of cardiac dysfunction in cancer patients

Immune checkpoint inhibitor cardiotoxicity: Breaking barriers in the cardiovascular immune landscape

Cardiotoxicity induced by immune checkpoint inhibitor: The complete insight into mechanisms, monitoring, diagnosis, and treatment

Metabolic Modifications, Inflammation, and Cancer Immunotherapy

Data from Interplay Between Immune Checkpoint Proteins and Cellular Metabolism

Cardio-onco-metabolism: metabolic remodelling in cardiovascular disease and cancer

Cardiovascular toxicity of immune therapies for cancer

Immune Checkpoint Inhibitor Cardiotoxicity: Understanding Basic Mechanisms and Clinical Characteristics and Finding a Cure